WuXi AppTec has helped advance drug development programs worldwide through more than two decades of collaboration with innovators. Across thousands of partnerships, the company has built its reputation not only on scale, but on its ability to deliver efficiency, solve complex scientific challenges, and connect different players across the global life sciences ecosystem. Together, these capabilities have established WuXi AppTec as a trusted partner in bringing new medicines from concept to reality.

Delivering Speed, Cost, and Quality Together

For many years, drug developers relied on in-house manufacturing. However, this model often led to duplicated investments, inefficiencies, and high barriers, especially for smaller biotech companies. WuXi AppTec was founded to change that dynamic by enabling a more efficient path from discovery to development and manufacturing.

At the center of this approach is WuXi AppTec’s integrated CRDMO model, which connects research, development, and manufacturing into one coordinated platform. By supporting projects end to end, this model reduces fragmentation and eliminates the need for innovators to manage multiple vendors across different stages.

For customers, the true value of integration goes beyond placing services under one roof. It means real-time coordination, shared visibility, and alignment across scientific teams and the client. By enabling multiple activities to run in parallel, timelines can be significantly accelerated while maintaining quality.

For example, a client developing a complex peptide once faced significant challenges. The team needed to complete a Chemistry, Manufacturing, and Controls (CMC) package for Investigational New Drug (IND) filing within 11 months, but the peptide synthesis could not be scaled up. After understanding the issues, WuXi AppTec’s teams worked on process development, formulation, analytical work, manufacturing, and regulatory writing simultaneously. As a result, the IND was submitted ahead of schedule, and the program has since advanced into a key stage with promising outcomes.

In conventional thinking, speed, cost, and quality are often seen as an “impossible triangle.” Through integrated execution, operational discipline, and a global capacity network, WuXi AppTec’s CRDMO model challenges that assumption and demonstrates that all three can be delivered together.

Solving Complex Scientific and Technical Challenges

Beyond efficiency, WuXi AppTec plays a critical role in helping clients overcome scientific barriers. One example comes from its WuXi TIDES platform, an integrated CRDMO platform supporting drug discovery, development, and manufacturing for oligonucleotides, peptides, and related conjugated medicines.

Around a decade ago, innovators developing peptide therapies faced a common challenge: peptides are composed of amino acids, and these amino acids have different geometric properties, much like left and right hands in humans.

At the time, only one external provider could perform the required test to analyze these properties. This meant all samples had to be shipped out for analysis, with results taking weeks to return, creating significant challenges for real time quality control.

Rather than accepting this limitation, the WuXi TIDES team developed its own in-house analytical method within a few months, enabling immediate feedback for clients during development.

This mindset extends across the platform. By combining multiple technologies with integrated execution, WuXi TIDES allows teams to work in parallel from discovery through manufacturing. In this way, the team continuously builds new capabilities to address the practical challenges clients face, turning scientific complexity into executable solutions that accelerate drug development.

As a result, many projects can complete the full CMC package required for IND filing approximately six months faster than the industry average.

Connecting the Needs of Biotech and Pharma

Biotech companies and large pharmaceutical companies operate differently, but they share similar needs: advancing pipelines quickly and improving cost efficiency. In addition, biotech companies seek ways to reach critical milestones and extend their cash runway, while pharmaceutical companies look for trusted partners with proven track records.

WuXi AppTec sits at the intersection of these needs, aligning its capabilities to support both ends of the spectrum.

In one case, a biotech client brought a challenge to WuXi AppTec. It needed to test thousands of new compounds within three months, a timeline considered impossible by other vendors.

To deliver for the client, WuXi AppTec designed a customized plan. Across its global sites, the teams leveraged automation platforms and coordinated studies to ensure a seamless workflow. The outcome exceeded expectations: 5,000 compounds were completed in vitro ADME assays and 1,000 compounds in vivo pharmacokinetic (PK) studies, all ahead of schedule. As the client’s CEO put it, “Without WuXi AppTec, this kind of speed wouldn’t be possible.”

For pharmaceutical companies, WuXi AppTec’s integrated platform not only enables them to advance individual programs, but also ensures that the right capabilities are assembled at the right time to deliver results efficiently. According to industry analysis, such models can reduce development and manufacturing costs by 30% to 60% while improving overall productivity.

Over time, these capabilities translate into trust. In one instance, WuXi AppTec helped a partner accelerate the launch of a cancer therapy by several months, allowing thousands of patients to begin treatment sooner. Years later, the company’s leadership returned and reaffirmed that future products would again be developed with WuXi AppTec.

In some cases, compounds supported by WuXi AppTec’s platform change ownership. Yet the pharmaceutical companies that acquire these programs often choose to continue working with WuXi AppTec.

These relationships illustrate a broader pattern. What begins as a single project often evolves into collaboration, and ultimately into long-term partnership. For many clients, WuXi AppTec is not only a service provider, but a consistent partner across multiple programs and over many years.

From Collaboration to Patient Impact

By integrating capabilities, solving complex scientific problems, and aligning with the evolving needs of both biotech and pharmaceutical companies, WuXi AppTec helps break down the barriers that often slow innovation.

After more than two decades, this approach has not only supported individual programs, but also strengthened the broader ecosystem of drug development. As new scientific ideas continue to emerge, WuXi AppTec remains positioned to help transform them into therapies for global patients.

Key Takeaways:

• WuXi AppTec enables global drug discovery and development: Through long-term collaboration with biotech and pharmaceutical companies, WuXi AppTec supports programs from discovery through development and manufacturing. 

• CRDMO integrates R + D + M into one platform: WuXi AppTec’s model connects research, development, and manufacturing to reduce fragmentation, improve coordination, and accelerate drug development timelines.

• WuXi AppTec’s CRDMO model improves speed, cost, and quality simultaneously: Parallel execution across scientific and manufacturing teams enables faster program advancement while maintaining high standards of quality and efficiency.

• Specialized platforms solve complex scientific challenges: Integrated capabilities such as the WuXi TIDES platform support oligonucleotide and peptide therapeutics by combining discovery, development, analytical, and manufacturing expertise. 

• WuXi AppTec’s global collaboration strengthens the drug development ecosystem: Through thousands of partnerships with biotech innovators and pharmaceutical companies, WuXi AppTec helps translate promising science into medicines for patients worldwide.